The 1bn is not being spent very well by the NIH. A lot of it went to organisations without the necessary infrastructure or expertise. They’re not conducting the necessary research to determine viral persistence.
The planned trials by the NIH are not very exciting, and are going slow.
The “private venture” is the organisation I’m affiliated with. It has a funding gap of ~80 million at the moment and is primarily funding constrained. I’ll write more about LCRI in a new post soon :)
Hey, thanks for the engagement.
The 1bn is not being spent very well by the NIH. A lot of it went to organisations without the necessary infrastructure or expertise. They’re not conducting the necessary research to determine viral persistence.
The planned trials by the NIH are not very exciting, and are going slow.
The “private venture” is the organisation I’m affiliated with. It has a funding gap of ~80 million at the moment and is primarily funding constrained. I’ll write more about LCRI in a new post soon :)